VITASPRING BIOMEDICAL CO. LTD.

VitaSpring Biomedical Co., Ltd. filed its 10-Q report for the period ending July 31, 2026. The company reported a net loss of $155,817 for the three-month period and $231,661 for the six-month period. Total assets stood at $14,822, while total liabilities reached $4,677,051, resulting in a significant accumulated deficit of $5,928,532. The company's cash balance was minimal at $13,367. A significant management and board transition occurred on September 7, 2026, with new leadership appointed. The company continues to face going concern issues due to its financial condition.